A Safety Study of IMOVAX Polio Vaccine in Selected Cities in China

Sanofi Pasteur, a Sanofi Company5,007 enrolled

Overview

The aim of the study is to collect post marketing safety data on IMOVAX Polio vaccine in China. Objective: To describe serious adverse events 30 days after each dose of IMOVAX Polio™ administered at 2, 3, and 4 months of age among infants living in the study cities of China.

Each study participant will receive an IMOVAX Polio™ injections at 2, 3 and 4 months of age (total of 3 doses) and will be followed up for 30 days after each vaccination.

Study Type

INTERVENTIONAL

Allocation

Purpose

PREVENTION

Masking

NONE

Enrollment

5,007

Conditions

Polio Poliomyelitis

Interventions

IMOVAX Polio™: Inactivated Poliomyelitis VaccineBIOLOGICAL

0.5 mL, Intramuscular

Eligibility

Sex: ALLMin age: 60 DaysMax age: 89 DaysHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Subject is 2 months of age or older (60-89days) when receiving the first dose of polio vaccine. * Subject's parent /legal representative showed willingness to complete the 3 primary doses fully using IMOVAX Polio according to the schedule. one injection at 2, 3, 4 months old respectively; * Informed consent form obtained by the subject's parent/legal representative. * Subject plan to live in the selected study sites for at least three months after inclusion. Exclusion Criteria: * Subject with a history of serious illness (i.e., hypersensitivity, seizure, convulsion, encephalopathy diseases, etc.) * Acute medical illness with or without fever within the last 72 hours. * Vaccination planned in the 4 weeks following any trial vaccination (except Diphtheria, Tetanus, Pertussis (DTP), Hib vaccine or Pneumo vaccine) * Participation in another clinical trial at the same time. * Contraindications to vaccination according to IMOVAX Polio™ leaflet. * Subject plan to leave the study sites for at least three months after inclusion.

Locations (15)

Unnamed facility

Beijing, Beijing Municipality, China

Unnamed facility

Changsha, China

Unnamed facility

Chengdu, China

Unnamed facility

Chongqing, China

Outcomes

Primary Outcomes

Number of participants reporting serious adverse events and relationship to Imovax Polio vaccination.

A serious adverse event is defined as any untoward medical occurrence that at any dose (including overdose) results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect, or is an important medical event.

Time frame: Up to 30 days after each vaccination

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.